Biliary Excretion and Pharmacokinetics of Ceftriaxone After Cholecystectomy

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 1986 Jan 1

PMID 3743620

Citations 19

Authors

W L Hayton

R Schandlik

K Stoeckel

Affiliations

Soon will be listed here.

Abstract

Three groups of patients with biliary tract disease treated by cholecystectomy were given ceftriaxone. In Group 1 single doses of 150 mg and 1500 mg were given on Days 1 and 5 after cholecystectomy. In Group 2 2 g was given daily for 6 days and the cholecystectomy was on Day 2. Patients in Group 3 received 2 g every 12 h for 3 to 5 doses before cholecystectomy. Plasma samples, urine and T-drain bile were collected at various times from Groups 1 and 2 patients. Gallbladder bile and plasma were collected from Group 3 patients at the time of cholecystectomy. The mean (+/- SEM) T-drain bile-to-plasma concentration ratio of ceftriaxone in Groups 1 and 2 was 6.7 +/- 0.92. The mean (+/- SEM) gallbladder bile-to-plasma concentration ratio was 33 +/- 4.2. No clinically significant differences were detected between the kinetics of ceftriaxone in the cholecystectomy patients compared to normal volunteers. The usual dosage of ceftriaxone appeared adequate for prophylaxis or treatment of biliary tract infection by susceptible organisms.

Citing Articles

Enterococcus faecium Clade Competition in the Presence of β-Lactam Antibiotics in a Mouse GI Tract Colonization Model.

Singh K, Montealegre M, Murray B Antimicrob Agents Chemother. 2022; 66(11):e0090322.

PMID: 36255277 PMC: 9664857. DOI: 10.1128/aac.00903-22.

There is Only One Valid Definition of Clearance: Critical Examination of Clearance Concepts Reveals the Potential for Errors in Clinical Drug Dosing Decisions.

Benet L, Sodhi J, Makrygiorgos G, Mesbah A AAPS J. 2021; 23(3):67.

PMID: 33973074 PMC: 8110503. DOI: 10.1208/s12248-021-00591-z.

Systemic Lupus Erythematosus-associated Acute Acalculous Cholecystitis Successfully Treated by a Corticosteroid Combined with Azathioprine.

Kudo N, Takaoka H, Shimomura T, Suzushima H, Fujiyama S Intern Med. 2019; 58(19):2879-2885.

PMID: 31243208 PMC: 6815888. DOI: 10.2169/internalmedicine.2820-19.

The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies.

Kokai-Kun J, Roberts T, Coughlin O, Sicard E, Rufiange M, Fedorak R Antimicrob Agents Chemother. 2017; 61(3).

PMID: 28052855 PMC: 5328510. DOI: 10.1128/AAC.02197-16.

Role of cephalosporins in the era of Clostridium difficile infection.

Wilcox M, Chalmers J, Nord C, Freeman J, Bouza E J Antimicrob Chemother. 2016; 72(1):1-18.

PMID: 27659735 PMC: 5161048. DOI: 10.1093/jac/dkw385.

References

Stoeckel K, Koup J . Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model. Am J Med. 1984; 77(4C):26-32. View

Hayton W, Stoeckel K . Age-associated changes in ceftriaxone pharmacokinetics. Clin Pharmacokinet. 1986; 11(1):76-86. DOI: 10.2165/00003088-198611010-00005. View

Richards D, Heel R, Brogden R, Speight T, Avery G . Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1984; 27(6):469-527. DOI: 10.2165/00003495-198427060-00001. View

Ratzan K, Baker H, Lauredo I . Excretion of cefamandole, cefazolin, and cephalothin into T-tube bile. Antimicrob Agents Chemother. 1978; 13(6):985-7. PMC: 352376. DOI: 10.1128/AAC.13.6.985. View

Kemmerich B, Lode H, Borner K, Belmega D, Jendroschek T, Koeppe P . Biliary excretion and pharmacokinetics of cefoperazone in humans. J Antimicrob Chemother. 1983; 12(1):27-37. DOI: 10.1093/jac/12.1.27. View

McNamara P, Gibaldi M, Stoeckel K . Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. I. Theoretical considerations. Eur J Clin Pharmacol. 1983; 25(3):399-405. DOI: 10.1007/BF01037955. View

Arvidsson A, Alvan G, Angelin B, Borga O, Nord C . Ceftriaxone: renal and biliary excretion and effect on the colon microflora. J Antimicrob Chemother. 1982; 10(3):207-15. DOI: 10.1093/jac/10.3.207. View

McNamara P, Stoeckel K, ZIEGLER W . Pharmacokinetics of ceftriaxone following intravenous administration of a 3 g dose. Eur J Clin Pharmacol. 1982; 22(1):71-5. DOI: 10.1007/BF00606428. View

Reichen J, Paumgartner G . Excretory function of the liver. Int Rev Physiol. 1980; 21:103-50. View

10.

Baumgartner J, Glauser M . Pharmacokinetic and microbial susceptibility studies of ceftriaxone. Eur J Clin Microbiol. 1983; 2(5):501-4. DOI: 10.1007/BF02013916. View

11.

Maudgal D, Maxwell J, Lees L, Wild R . Biliary excretion of amoxycillin and ceftriaxone after intravenous administration in man. Br J Clin Pharmacol. 1982; 14(2):213-7. PMC: 1427740. DOI: 10.1111/j.1365-2125.1982.tb01964.x. View

12.

Strange R . Hepatic bile flow. Physiol Rev. 1984; 64(4):1055-102. DOI: 10.1152/physrev.1984.64.4.1055. View

13.

Stoeckel K, McNamara P, Brandt R, ZIEGLER W . Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics. Clin Pharmacol Ther. 1981; 29(5):650-7. DOI: 10.1038/clpt.1981.90. View

14.

Brogard J, Arnaud J, Timmler R . Biliary excretion of ceftizoxime in humans. Chemotherapy. 1984; 30(4):221-6. DOI: 10.1159/000238272. View

15.

McNamara P, Gibaldi M, Stoeckel K . Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. II. Physiological significance. Eur J Clin Pharmacol. 1983; 25(3):407-12. DOI: 10.1007/BF01037956. View

16.

Farquet C, Marti M, Balant L, Cochet B, RUDHARDT M, Fabre J . [Pharmacokinetic study of a cephalosporin: cefoperazone in patients with a Kehr drain]. Schweiz Med Wochenschr. 1982; 112(4):123-9. View

17.

Stoeckel K, Tuerk H, Trueb V, McNamara P . Single-dose ceftriaxone kinetics in liver insufficiency. Clin Pharmacol Ther. 1984; 36(4):500-9. DOI: 10.1038/clpt.1984.210. View